NCT05088356 2025-12-19
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Stanford University
Phase 1 Recruiting
Clinical Trials
15 trialsNCT03240861 2023-11-01
NYESO SCT
Jonsson Comprehensive Cancer Center
Phase 1 Terminated
NCT03506802 2020-07-24
NYSCT MM
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn
NCT03277209 2020-03-02
To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas
Weill Medical College of Cornell University
Phase 1 Terminated
NCT02179970 2019-07-23
CAM-PLEX
Cambridge University Hospitals NHS Foundation Trust
Phase 1 Completed
NCT02343666 2018-11-20
HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection
Fred Hutchinson Cancer Center
Phase 1 Withdrawn
NCT01319864 2018-09-07
POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients
Seattle Children's Hospital
Phase 1 Completed
NCT01352650 2018-07-02
Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)
Weill Medical College of Cornell University
Phase 1 Completed
NCT01373229 2018-02-05
Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)
Duke University
Phase 1 Completed
NCT01339039 2017-11-17
Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT01610999 2017-05-09
Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation
Tufts Medical Center
Phase 1 Terminated
NCT00943943 2017-03-29
Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01027923 2015-01-26
AML
Washington University School of Medicine
Phase 1 Terminated
NCT01068301 2014-01-01
A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation
St. Jude Children's Research Hospital
Phase 1 Completed
NCT01074060 2013-02-15
Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma
City of Hope Medical Center
Phase 1 Completed